BIIB Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

178.405

Open

176.290

VWAP

177.15

Vol

1.24M

Mkt Cap

26.03B

Low

175.690

Amount

219.57M

EV/EBITDA(TTM)

7.91

Total Shares

146.76M

28.30B

EV/OCF(TTM)

12.84

P/S(TTM)

2.61

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Events Timeline

(ET)

2026-04-06

06:40:00

Biogen Expects Q1 2026 Net Income Per Share to Decrease by Approximately $0.19

News

6.0

04-17NASDAQ.COM

Three Stocks with Upgraded Ratings as Markets Reach New Highs

9.5

04-16Fool

Biogen Faces Challenges but Future Potential Remains

9.5

04-16NASDAQ.COM

Biogen's Quarterly Performance Lags, Future Uncertain

8.5

04-14seekingalpha

Biogen Shares Rise After Upgrade and Acquisition Announcement

6.0

04-14CNBC

Biogen Upgraded by Piper Sandler, Growth Prospects Remain Positive

6.0

04-14CNBC

Latest Rating Changes on Wall Street

26 Analyst Rating

Wall Street analysts forecast BIIB stock price to rise

11 Buy

14 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

143.00

Averages

204.45

High

246.00

Current: 0.000

Low

143.00

Averages

204.45

High

246.00

Piper Sandler

Neutral -> Overweight

upgrade

$177 -> $214

AI Analysis

2026-04-13

Reason

Piper Sandler

Price Target

$177 -> $214

AI Analysis

2026-04-13

upgrade

Neutral -> Overweight

Reason

Piper Sandler upgraded Biogen (BIIB) to Overweight from Neutral with a price target of $214, up from $177. The company's acquisition of Apellis Pharmaceuticals (APLS) brings new drugs to fill the gap created by its declining legacy multiple sclerosis franchise, the analyst tells investors in a research note. Piper believes the addition of Syfovre and Empaveli "at a minimum fills a gap" created by Biogen's loss of exclusivity exposure for its legacy multiple sclerosis assets.

Truist

Hold

maintain

$193 -> $189

2026-04-13

Reason

Truist

Price Target

$193 -> $189

2026-04-13

maintain

Hold

Reason

Truist lowered the firm's price target on Biogen to $189 from $193 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results among Biotech names. The firm is adjusting its model with modest down revision driven primarily by incorporation of the expected financial impacts from the recently announced $5.6B acquisition of Apellis, including forecasts for its commercial stage assets Syfovre and Empaveli into its sales projections, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BIIB

Unlock Now

Valuation Metrics

The current forward P/E ratio for Biogen Inc (BIIB.O) is 12.17, compared to its 5-year average forward P/E of 13.92. For a more detailed relative valuation and DCF analysis to assess Biogen Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

13.92

Current PE

12.17

Overvalued PE

17.42

Undervalued PE

10.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.38

Current EV/EBITDA

11.37

Overvalued EV/EBITDA

12.75

Undervalued EV/EBITDA

8.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.35

Current PS

2.76

Overvalued PS

4.17

Undervalued PS

2.54

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Stocks for short term gans

Intellectia · 19 candidates

Market Cap: >= 2.00BRsi Category: moderate, overboughtRelative Vol: >= 2Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00

Ticker

Name

Market Cap$

LBTYB

Liberty Global Ltd

6.07B

PAHC

Phibro Animal Health Corp

2.15B

ALGT

Allegiant Travel Co

2.10B

NVST

Envista Holdings Corp

4.77B

XPO

XPO Inc

23.85B

RRX

Regal Rexnord Corp

14.06B

NASDAQ100 stock with fairly or undervalue

Intellectia · 10 candidates

Analyst Consensus: Strong Buy, Moderate Buy, HoldPe Ttm: 8 - 22P/B Ratio: <= 4.00Is Index Component: NDXEv Ebitda: <= 15

Ticker

Name

Market Cap$

FANG

Diamondback Energy Inc

44.13B

PDD

PDD Holdings Inc

152.56B

PYPL

PayPal Holdings Inc

53.15B

BIIB

Biogen Inc

25.32B

TMUS

T-Mobile US Inc

211.11B

CTSH

Cognizant Technology Solutions Corp

41.28B

list of biotech stock

Intellectia · 11 candidates

Market Cap: >= 1000.00MThemes: BiotechBeta: LowRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True

Ticker

Name

Market Cap$

AMGN

Amgen Inc

185.02B

GILD

Gilead Sciences Inc

160.18B

VRTX

Vertex Pharmaceuticals Inc

117.00B

REGN

Regeneron Pharmaceuticals Inc

78.75B

BNTX

Biontech SE

29.61B

BIIB

Biogen Inc

25.32B

show me onlybiostock

Intellectia · 19 candidates

Themes: BiotechWeekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

AMGN

Amgen Inc

185.02B

GILD

Gilead Sciences Inc

160.18B

VRTX

Vertex Pharmaceuticals Inc

117.00B

REGN

Regeneron Pharmaceuticals Inc

78.75B

BNTX

Biontech SE

29.61B

BIIB

Biogen Inc

25.32B

Whales Holding BIIB

MAPFRE Asset Management

Mubadala Investment Company PJSC

Point72 Asset Management, L.P.

Hudson River Trading LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biogen Inc (BIIB) stock price today?

The current price of BIIB is 177.35 USD — it has increased 0.76

What is Biogen Inc (BIIB)'s business?

What is the price predicton of BIIB Stock?

Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is204.45 USD with a low forecast of 143.00 USD and a high forecast of 246.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Biogen Inc (BIIB)'s revenue for the last quarter?

Biogen Inc revenue for the last quarter amounts to 2.28B USD, decreased -7.14

What is Biogen Inc (BIIB)'s earnings per share (EPS) for the last quarter?

Biogen Inc. EPS for the last quarter amounts to -0.33 USD, decreased -118.03

How many employees does Biogen Inc (BIIB). have?

Biogen Inc (BIIB) has 7500 emplpoyees as of April 20 2026.

What is Biogen Inc (BIIB) market cap?

Today BIIB has the market capitalization of 26.03B USD.

BIIB Overview

BIIB Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding BIIB

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biogen Inc (BIIB) stock price today?

What is Biogen Inc (BIIB)'s business?

What is the price predicton of BIIB Stock?

What is Biogen Inc (BIIB)'s revenue for the last quarter?

What is Biogen Inc (BIIB)'s earnings per share (EPS) for the last quarter?

How many employees does Biogen Inc (BIIB). have?

What is Biogen Inc (BIIB) market cap?